UNSPSC 51321805: Clofibrate

This classification denotes an anti-lipidemic agent with the molecular formula C12H15ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HPN91K7FU3, chemically known as piperazine, 1- (diphenylmethyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as clofibrate, which bears US NIH Compound Identifier 2761. European Medicines Agency schedules Clofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06706MIG.

UNSPSC 51321805 Clofibrate, a Commodity code, covers individual pharmaceutical ingredients and finished medications procured by state and local health agencies, emergency services, and public-sector pharmacy benefit programs. State and local governments buy clofibrate and related generic pharmaceuticals through direct supply contracts with manufacturers, cooperative purchasing vehicles, and emergency-response medication procurement. The issuing bodies include city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state and local member agencies. Recent solicitations show governments sourcing both advanced life support medications for emergency medical transport and generic pharmaceutical inventories through centralized state-level procurement systems.

Activity under this code spans Florida, Texas, and Minnesota-based cooperative purchasing networks. The City of Tampa's Purchasing Department issued IFB 26P00188 (due April 8, 2026) for Advanced Life Support Medications, including epinephrine, labetalol, adenosine, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year base term plus renewal options and small local business enterprise set-asides. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level movement toward direct manufacturer contracting outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed to state and local government facilities in Minnesota and Oregon, requiring manufacturers to maintain relationships with three authorized wholesalers and comply with Good Manufacturing Practices and Drug Supply Chain Security Act standards.